PATENT CLAIM ANALYSIS

Application Number: 15991313
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "178000"]

Abstract:
Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: is specifically disclosed for the medical treatment and/or inhibition of development of some of these above-mentioned diseases. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.

Claim (Index 3):
The method of  claim 2 , wherein the selective estrogen receptor modulator is:

Metadata:
- Claim Count in Document: 56.0
- Percentile: 93.0
- Lexical Diversity: 1.51685
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14464536', '13875027', '15626774', '14638763', '09405678']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7762723525410465
- 35 USC 102 Novelty (BERT): 0.712316982893656
- Combined Prediction Score: 0.7698768155763075
- Mean Citation Score: 522.0052320000002
- Max Citation Score: 829.57025
- Similarity Product: 736.9361804703772

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test